1+ week, 1+ hour ago   (69+ words) Reformed pharmaceutical regulation across India’s drug landscape pharmaceutical-technology.com Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile,…...

2+ week, 45+ min ago   (476+ words) In Association with Cencora Launching a product across Europe’s fragmented healthcare systems presents unique challenges that first-timers are often unprepared for, say experts from Cencora. How can emerging biotechs navigate the risks, accelerate market entry, and prevent launches from derailing?...

3+ week, 6+ day ago   (452+ words) Regulatory shifts across life sciences have come at an unprecedented pace in 2026. Yet, despite noncompliance risks, a fragmented, legacy-based compliance approach still dominates manufacturing. Data integrity has become a defining compliance risk. Paper-based systems and hybrid environments where data is…...

1+ mon, 5+ day ago   (400+ words) While UK biotech financing recovery is present in the private markets, BIA CEO Chris Molloy notes that UK public sector backing is essential for sustained growth. After navigating a challenging funding landscape in 2025, the UK biotech sector appears to be…...

1+ mon, 3+ week ago   (900+ words) Celebrity ambassadors in pharma and medtech herald a new dawn of direct-to-consumer advertising. For years, Serena Williams was the defining face of women’s tennis. Now, her ongoing alliance with a telehealth company may be signifying a broader shift in US…...

2+ mon, 2+ hour ago   (214+ words) In Association with GlobalData Hiring intent is a leading indicator, but quantifying it systematically enough to generate durable, repeatable alpha is a problem. Here, we examine the interval between what companies are building and when it surfaces publicly and why…...

2+ mon, 9+ hour ago   (249+ words) Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors. Funding cuts at US federal agencies have compounded threats to the US’s predominance in global biopharma as an ascendant Chinese…...

2+ mon, 6+ day ago   (475+ words) Amidst regulatory turmoil and a funding resurgence, companies provide insights on how they are navigating the changing industry. Following an influx of capital in the early COVID-19 pandemic, the biotech sector entered a sustained investment slump. Now the industry finally…...

2+ mon, 1+ week ago   (247+ words) Pharmaceutical Technology Rare disease R&D investment is outpacing the broader biotech market, while the pipeline of innovative therapies continues to deepen. With enhanced sequencing and data infrastructure, Europe’s constraint is no longer scientific. Funding and regulatory complexity remain the…...

2+ mon, 2+ week ago   (985+ words) While the regulatory landscape around biosimilars is evolving to encourage efficiency and innovation, the commercial landscape is playing catch-up as the biosimilar void persists. As the pharmacological treatment landscape continues to evolve, biologics are becoming increasingly incorporated into therapeutic regimens…...